Cargando…

Validation of ketamine as a pharmacological model of thalamic dysconnectivity across the illness course of schizophrenia

N-methyl-D-aspartate receptor (NMDAR) hypofunction is a leading pathophysiological model of schizophrenia. Resting-state functional magnetic resonance imaging (rsfMRI) studies demonstrate a thalamic dysconnectivity pattern in schizophrenia involving excessive connectivity with sensory regions and de...

Descripción completa

Detalles Bibliográficos
Autores principales: Abram, Samantha V., Roach, Brian J., Fryer, Susanna L., Calhoun, Vince D., Preda, Adrian, van Erp, Theo G. M., Bustillo, Juan R., Lim, Kelvin O., Loewy, Rachel L., Stuart, Barbara K., Krystal, John H., Ford, Judith M., Mathalon, Daniel H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9135621/
https://www.ncbi.nlm.nih.gov/pubmed/35422467
http://dx.doi.org/10.1038/s41380-022-01502-0
_version_ 1784714000909467648
author Abram, Samantha V.
Roach, Brian J.
Fryer, Susanna L.
Calhoun, Vince D.
Preda, Adrian
van Erp, Theo G. M.
Bustillo, Juan R.
Lim, Kelvin O.
Loewy, Rachel L.
Stuart, Barbara K.
Krystal, John H.
Ford, Judith M.
Mathalon, Daniel H.
author_facet Abram, Samantha V.
Roach, Brian J.
Fryer, Susanna L.
Calhoun, Vince D.
Preda, Adrian
van Erp, Theo G. M.
Bustillo, Juan R.
Lim, Kelvin O.
Loewy, Rachel L.
Stuart, Barbara K.
Krystal, John H.
Ford, Judith M.
Mathalon, Daniel H.
author_sort Abram, Samantha V.
collection PubMed
description N-methyl-D-aspartate receptor (NMDAR) hypofunction is a leading pathophysiological model of schizophrenia. Resting-state functional magnetic resonance imaging (rsfMRI) studies demonstrate a thalamic dysconnectivity pattern in schizophrenia involving excessive connectivity with sensory regions and deficient connectivity with frontal, cerebellar, and thalamic regions. The NMDAR antagonist ketamine, when administered at sub-anesthetic doses to healthy volunteers, induces transient schizophrenia-like symptoms and alters rsfMRI thalamic connectivity. However, the extent to which ketamine-induced thalamic dysconnectivity resembles schizophrenia thalamic dysconnectivity has not been directly tested. The current double-blind, placebo-controlled study derived an NMDAR hypofunction model of thalamic dysconnectivity from healthy volunteers undergoing ketamine infusions during rsfMRI. To assess whether ketamine-induced thalamic dysconnectivity was mediated by excess glutamate release, we tested whether pre-treatment with lamotrigine, a glutamate release inhibitor, attenuated ketamine’s effects. Ketamine produced robust thalamo-cortical hyper-connectivity with sensory and motor regions that was not reduced by lamotrigine pre-treatment. To test whether the ketamine thalamic dysconnectivity pattern resembled the schizophrenia pattern, a whole-brain template representing ketamine’s thalamic dysconnectivity effect was correlated with individual participant rsfMRI thalamic dysconnectivity maps, generating “ketamine similarity coefficients” for people with chronic (SZ) and early illness (ESZ) schizophrenia, individuals at clinical high-risk for psychosis (CHR-P), and healthy controls (HC). Similarity coefficients were higher in SZ and ESZ than in HC, with CHR-P showing an intermediate trend. Higher ketamine similarity coefficients correlated with greater hallucination severity in SZ. Thus, NMDAR hypofunction, modeled with ketamine, reproduces the thalamic hyper-connectivity observed in schizophrenia across its illness course, including the CHR-P period preceding psychosis onset, and may contribute to hallucination severity.
format Online
Article
Text
id pubmed-9135621
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-91356212022-05-28 Validation of ketamine as a pharmacological model of thalamic dysconnectivity across the illness course of schizophrenia Abram, Samantha V. Roach, Brian J. Fryer, Susanna L. Calhoun, Vince D. Preda, Adrian van Erp, Theo G. M. Bustillo, Juan R. Lim, Kelvin O. Loewy, Rachel L. Stuart, Barbara K. Krystal, John H. Ford, Judith M. Mathalon, Daniel H. Mol Psychiatry Article N-methyl-D-aspartate receptor (NMDAR) hypofunction is a leading pathophysiological model of schizophrenia. Resting-state functional magnetic resonance imaging (rsfMRI) studies demonstrate a thalamic dysconnectivity pattern in schizophrenia involving excessive connectivity with sensory regions and deficient connectivity with frontal, cerebellar, and thalamic regions. The NMDAR antagonist ketamine, when administered at sub-anesthetic doses to healthy volunteers, induces transient schizophrenia-like symptoms and alters rsfMRI thalamic connectivity. However, the extent to which ketamine-induced thalamic dysconnectivity resembles schizophrenia thalamic dysconnectivity has not been directly tested. The current double-blind, placebo-controlled study derived an NMDAR hypofunction model of thalamic dysconnectivity from healthy volunteers undergoing ketamine infusions during rsfMRI. To assess whether ketamine-induced thalamic dysconnectivity was mediated by excess glutamate release, we tested whether pre-treatment with lamotrigine, a glutamate release inhibitor, attenuated ketamine’s effects. Ketamine produced robust thalamo-cortical hyper-connectivity with sensory and motor regions that was not reduced by lamotrigine pre-treatment. To test whether the ketamine thalamic dysconnectivity pattern resembled the schizophrenia pattern, a whole-brain template representing ketamine’s thalamic dysconnectivity effect was correlated with individual participant rsfMRI thalamic dysconnectivity maps, generating “ketamine similarity coefficients” for people with chronic (SZ) and early illness (ESZ) schizophrenia, individuals at clinical high-risk for psychosis (CHR-P), and healthy controls (HC). Similarity coefficients were higher in SZ and ESZ than in HC, with CHR-P showing an intermediate trend. Higher ketamine similarity coefficients correlated with greater hallucination severity in SZ. Thus, NMDAR hypofunction, modeled with ketamine, reproduces the thalamic hyper-connectivity observed in schizophrenia across its illness course, including the CHR-P period preceding psychosis onset, and may contribute to hallucination severity. Nature Publishing Group UK 2022-04-14 2022 /pmc/articles/PMC9135621/ /pubmed/35422467 http://dx.doi.org/10.1038/s41380-022-01502-0 Text en © This is a U.S. government work and not under copyright protection in the U.S.; foreign copyright protection may apply 2022 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Article
Abram, Samantha V.
Roach, Brian J.
Fryer, Susanna L.
Calhoun, Vince D.
Preda, Adrian
van Erp, Theo G. M.
Bustillo, Juan R.
Lim, Kelvin O.
Loewy, Rachel L.
Stuart, Barbara K.
Krystal, John H.
Ford, Judith M.
Mathalon, Daniel H.
Validation of ketamine as a pharmacological model of thalamic dysconnectivity across the illness course of schizophrenia
title Validation of ketamine as a pharmacological model of thalamic dysconnectivity across the illness course of schizophrenia
title_full Validation of ketamine as a pharmacological model of thalamic dysconnectivity across the illness course of schizophrenia
title_fullStr Validation of ketamine as a pharmacological model of thalamic dysconnectivity across the illness course of schizophrenia
title_full_unstemmed Validation of ketamine as a pharmacological model of thalamic dysconnectivity across the illness course of schizophrenia
title_short Validation of ketamine as a pharmacological model of thalamic dysconnectivity across the illness course of schizophrenia
title_sort validation of ketamine as a pharmacological model of thalamic dysconnectivity across the illness course of schizophrenia
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9135621/
https://www.ncbi.nlm.nih.gov/pubmed/35422467
http://dx.doi.org/10.1038/s41380-022-01502-0
work_keys_str_mv AT abramsamanthav validationofketamineasapharmacologicalmodelofthalamicdysconnectivityacrosstheillnesscourseofschizophrenia
AT roachbrianj validationofketamineasapharmacologicalmodelofthalamicdysconnectivityacrosstheillnesscourseofschizophrenia
AT fryersusannal validationofketamineasapharmacologicalmodelofthalamicdysconnectivityacrosstheillnesscourseofschizophrenia
AT calhounvinced validationofketamineasapharmacologicalmodelofthalamicdysconnectivityacrosstheillnesscourseofschizophrenia
AT predaadrian validationofketamineasapharmacologicalmodelofthalamicdysconnectivityacrosstheillnesscourseofschizophrenia
AT vanerptheogm validationofketamineasapharmacologicalmodelofthalamicdysconnectivityacrosstheillnesscourseofschizophrenia
AT bustillojuanr validationofketamineasapharmacologicalmodelofthalamicdysconnectivityacrosstheillnesscourseofschizophrenia
AT limkelvino validationofketamineasapharmacologicalmodelofthalamicdysconnectivityacrosstheillnesscourseofschizophrenia
AT loewyrachell validationofketamineasapharmacologicalmodelofthalamicdysconnectivityacrosstheillnesscourseofschizophrenia
AT stuartbarbarak validationofketamineasapharmacologicalmodelofthalamicdysconnectivityacrosstheillnesscourseofschizophrenia
AT krystaljohnh validationofketamineasapharmacologicalmodelofthalamicdysconnectivityacrosstheillnesscourseofschizophrenia
AT fordjudithm validationofketamineasapharmacologicalmodelofthalamicdysconnectivityacrosstheillnesscourseofschizophrenia
AT mathalondanielh validationofketamineasapharmacologicalmodelofthalamicdysconnectivityacrosstheillnesscourseofschizophrenia